OptiNose Inc  

(Public, NASDAQ:OPTN)   Watch this stock  
Find more results for OPTN
-0.26 (-1.34%)
After Hours: 19.10 0.00 (0.00%)
Jan 17, 4:27PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.75 - 19.62
52 week 15.01 - 21.50
Open 19.39
Vol / Avg. 0.00/153,068.00
Mkt cap 722.32M
P/E     -
Div/yield     -
EPS -4.96
Shares 37.82M
Beta     -
Inst. own 13%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - 47.61%
Operating margin - 53.31%
EBITD margin - 53.48%
Return on average assets -88.02% 78.57%
Return on average equity - -
Employees 35 -
CDP Score - -


1020 Stony Hill Rd Ste 300
YARDLEY, PA 19067-5539
United States - Map
+1-267-3643500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.